Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Actavis plc
IndexS&P 500 P/E- EPS (ttm)-4.18 Insider Own0.10% Shs Outstand265.06M Perf Week6.98%
Market Cap68.52B Forward P/E15.70 EPS next Y16.46 Insider Trans-0.04% Shs Float264.08M Perf Month11.70%
Income-1046.00M PEG- EPS next Q3.49 Inst Own78.00% Short Float0.76% Perf Quarter13.72%
Sales11.78B P/S5.81 EPS this Y-793.40% Inst Trans15.86% Short Ratio0.74 Perf Half Y20.92%
Book/sh110.26 P/B2.34 EPS next Y21.49% ROA-3.10% Target Price274.90 Perf Year58.39%
Cash/sh1.28 P/C201.28 EPS next 5Y22.44% ROE-6.60% 52W Range156.40 - 270.34 Perf YTD53.86%
Dividend- P/FCF40.63 EPS past 5Y-35.20% ROI-3.00% 52W High-4.17% Beta0.30
Dividend %- Quick Ratio0.80 Sales past 5Y27.90% Gross Margin49.60% 52W Low65.65% ATR8.30
Employees19200 Current Ratio1.40 Sales Q/Q83.00% Oper. Margin-0.20% RSI (14)60.75 Volatility4.17% 2.96%
OptionableYes Debt/Eq0.53 EPS Q/Q-906.10% Profit Margin-8.10% Rel Volume2.10 Prev Close258.49
ShortableYes LT Debt/Eq0.52 EarningsNov 05 BMO Payout- Avg Volume2.71M Price259.08
Recom1.70 SMA204.95% SMA507.67% SMA20018.18% Volume2,614,600 Change0.23%
Nov-21-14Reiterated Argus Buy $285 → $310
Nov-20-14Reiterated RBC Capital Mkts Top Pick $291 → $323
Nov-18-14Reiterated UBS Buy $278 → $333
Nov-06-14Reiterated RBC Capital Mkts Top Pick $286 → $291
Sep-22-14Downgrade Barclays Overweight → Equal Weight $250 → $250
Aug-06-14Reiterated UBS Buy $237 → $254
Jul-02-14Reiterated CRT Capital Buy $245 → $275
Jun-27-14Initiated Canaccord Genuity Buy $275
May-12-14Upgrade RBC Capital Mkts Outperform → Top Pick $252 → $259
May-01-14Reiterated CRT Capital Buy $230 → $245
Apr-28-14Reiterated National Alliance Securities Buy $246 → $259
Apr-17-14Initiated National Alliance Securities Buy $246
Feb-21-14Reiterated RBC Capital Mkts Outperform $240 → $249
Feb-19-14Reiterated UBS Buy $202 → $237
Feb-19-14Reiterated CRT Capital Buy $210 → $230
Feb-19-14Reiterated Barclays Overweight $230 → $250
Feb-03-14Reiterated RBC Capital Mkts Outperform $202 → $222
Feb-03-14Reiterated Barclays Overweight $190 → $230
Jan-17-14Reiterated Argus Buy $180 → $198
Jan-07-14Initiated RBC Capital Mkts Outperform $202
Nov-21-14 12:23PM  If You Don't Own Apple, Actavis and Alibaba, Go Back To Sleep at Forbes
08:26AM  Allergan deal sits well on Actavis chief's 'Monopoly board' at Financial Times
04:11AM  After losing out over Allergan, Valeant announces $2 billion buyback at Fortune
Nov-20-14 03:34PM  Synergy Pharmaceuticals Drug Fares Well in Phase II Study Zacks
12:13PM  [$$] Valeant Sets $2 Billion Buyback Plan at The Wall Street Journal
Nov-19-14 05:35PM  Mallinckrodt Q4 Earnings Beat Views, But Outlook Hazy at Investor's Business Daily
04:10PM  Celgene Up on Encouraging Long-Term Phase III Otezla Data Zacks
11:42AM  Mallinckrodt Earnings Beat But No New Guidance at Investor's Business Daily
10:26AM  US stocks retreat from records before Fed release at CNBC
08:37AM  Allergan's Price Tag Gets Even Richer at The Wall Street Journal
07:58AM  The Zacks Analyst Blog Highlights: Actavis, Allergan, iShares U.S. Pharmaceuticals ETF, Market Vectors Pharmaceutical ETF and SPDR S&P Pharmaceuticals ETF Zacks
Nov-18-14 06:26PM  Stocks rally: Dow, S&P 500 set closing highs at USA TODAY +8.74%
06:15PM  [$$] Jack Lew, Irish Hero at The Wall Street Journal
06:00PM  Cramer shares hazards of skepticism CNBC
05:04PM  Vipshop, Jack in the Box Rise In After-Hours Trading at Investor's Business Daily
04:35PM  S&P, Dow ring up records Tuesday at MarketWatch
03:16PM  PetSmart, Jack in the Box earnings in focus after hours at MarketWatch
03:15PM  Zoetis 2015 Guidance Misses As Buyout Theories Abound at Investor's Business Daily
03:02PM  Actavis: One Day Later, Investors Really Like Allergan Acquisition at
02:58PM  [$$] Actavis-Allergan Deal Friendly to Shareholders at
02:38PM  Stock Movers: Why 4 Big Drug Stocks Are Rising Today at Investor's Business Daily
01:53PM  Deals Heat Up for Lawyers Like Its 1998 Bloomberg
01:38PM  Ackman supports Allergan's $66 billion sale to Actavis Reuters
01:35PM  ZOETIS SHARES ARE HALTED Business Insider
01:33PM  Stocks Hold Near Fresh Milestones; Actavis Hits New High at Investor's Business Daily
01:10PM  Ackman Pledges Support For Actavis Bid On Allergan Benzinga
12:30PM  Actavis shares outpace buyout targets gains at MarketWatch
12:20PM  Actavis Strikes $66 Billion Deal for Botox Maker Allergan Zacks
12:08PM  Ackman withdraws special Allergan meeting CNBC
11:47AM  Jim Cramer: Which Stocks Stand Out as Winners? Here's My List at TheStreet
11:45AM  Ackman says supports Allergan's $66 billion sale to Actavis: CNBC Reuters
11:43AM  Ackman says supports Allergan's $66 billion sale to Actavis -CNBC Reuters
11:29AM  Dealpolitik: Praise for Allergan Directors, Not Pershing Square at The Wall Street Journal
11:14AM  Actavis (ACT) Is Today's Unusual Social Activity Stock at TheStreet
11:06AM  One Factor Driving Up Actavis (ACT) Stock Today at TheStreet
10:33AM  Stocks Most Loved By Hedge Funds at
10:27AM  Ackman to CNBC: Support Actavis-Allergan deal CNBC
09:10AM  Cramer: Waiting for Santa Claus rally CNBC
09:03AM  [$$] Actavis Outlines Allergan Breakup Fee at The Wall Street Journal
08:51AM  Cramer's stocks to watch: AAPL, AGN & HD CNBC
08:44AM  Citi Raises Price Target On Actavis Benzinga
08:11AM  ACTAVIS PLC Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Financial Statements and Exhibits EDGAR Online
06:26AM  Zacks Investment Ideas feature highlights: Allergan, Actavis, Sketchers and Zeltiq Aesthetics Zacks
06:08AM  Actavis' dealmaking builds drug powerhouse at Financial Times
01:09AM  PRESS DIGEST - Wall Street Journal - Nov 18 Reuters
12:40AM  Actavis Agrees to Buy Botox Maker Allergan at The Wall Street Journal
12:39AM  Jack Lew, Irish Hero at The Wall Street Journal
Nov-17-14 08:39PM  Actavis to buy Botox maker Allergan for $66B at USA TODAY
08:00PM  [$$] Actavis to Buy Allergan for $66 Billion at The Wall Street Journal
06:45PM  Here Are Some Big Caps Poised To Make Gains at Investor's Business Daily
06:44PM  Actavis Surges to Top Drugmaker Ranks With Plan to Broaden Sales at Bloomberg
05:34PM  Ownership Roundup: Buffett and the Hedge Funds at 3Q at
05:31PM  Actavis Will Acquire Botox Firm Allergan For Over $66 Billion Investor's Business Daily
05:29PM  ACTAVIS PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits EDGAR Online
05:16PM  Allergan Sides With More Aggressive Dealmaker By Picking Actavis Over Valeant at Forbes
05:01PM  Actavis to spend $66 billion on Allergan AP
04:43PM  Today's quick look at the Market... Yahoo Finance Blogs
04:38PM  Allergan CEO hands Botox maker to lawyer instead of consultant at Fortune
04:29PM  Allergan agrees to $66 billion Actavis offer; Valeant walks Reuters
04:27PM  Allergan agrees to $66 bln Actavis offer; Valeant walks Reuters
04:16PM  Stocks End Mixed As Allergan Jumps On Actavis Deal at Investor's Business Daily
04:05PM  Allergan sees off Valeant by sealing $66bn deal with Actavis at Financial Times
03:18PM  Ackman win-win CNBC
03:13PM  Stocks Mixed In Afternoon; Allergan Jumps To New High at Investor's Business Daily
01:40PM  [video]Actavis Announces Deal to Acquire Botox Maker Allergan for $66B at TheStreet
01:38PM  [$$] Actavis-Allergan Deal Paves Way for Tax Savings at The Wall Street Journal
01:24PM  And The Winners Are Actavis, Allergan And Ackman at Forbes
01:23PM  U.S. Industrial Output Falls in October at Bloomberg
01:21PM  Actavis/Allergan: spoiler alert at Financial Times
01:05PM  Allergan-Actavis deal follows battle for soul of pharma at Financial Times
12:53PM  Bill Ackman's $2.2 Billion Day at The Wall Street Journal
12:35PM  Zoetis attractive & durable: Pro CNBC
12:33PM  Hedge fund winners in Allergan deal CNBC
12:32PM  [video] Ebola Patient Dies in Nebraska at Bloomberg
12:10PM  Actavis to spend $66B on Allergan AP
11:55AM  Done deal: Actavis buying Allergan for $66 billion at CNBC
11:54AM  Actavis Agrees to Buy Allergan for $66B at Bloomberg
11:27AM  Allergan thwarts Valeant with $66-billion Actavis deal at Los Angeles Times
11:11AM  Actavis to Buy Allergan for $66 Billion at MarketWatch
11:05AM  Second Ebola Death in U.S. at MarketWatch
10:59AM  Japan's Current Recession May Delay Abes Tax Hike at Bloomberg
10:59AM  Allergan's $66 Billion Actavis Deal is Still a Win for Bill Ackman TheStreet
10:55AM  Market Likes the Actavis-Allergan Deal at The Wall Street Journal
10:40AM  Allergan Agrees To $219 A Share Actavis Takeover Over Bill Ackman-Backed Valeant Deal at Forbes
10:32AM  ALLERGAN, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout PR Newswire
10:27AM  Valeant Left Out, Actavis Acquires Allergan in $66B Deal at Bloomberg
10:19AM  Actavis-Allergan Deal: Will Ackman Step in the Way? at MarketWatch
10:17AM  Actavis Nabs Allergan For $66 Billion; Valeant Folds at Investor's Business Daily
10:14AM  Actavis Tops Valeant Bid to Acquire Allergan in $66B Deal at Bloomberg
10:07AM  Botox maker bought for $66 billion in biggest deal of 2014 at
10:05AM  Allergan Accepts Buyout Offer From Actavis, Valeant Bows Out at 24/7 Wall St.
10:00AM  Actavis to Buy Allergan for $66 Billion, Tops Valeant Bid Bloomberg
09:50AM  Merger Madness: Deals Top $100 Billion on a Manic Monday at The Wall Street Journal
09:35AM  Actavis to buy Allergan in $66 billion deal at MarketWatch
09:29AM  Valeant Comments On Allergan Announcement PR Newswire
09:17AM  Actavis to Acquire Allergan for $66 Billion at Fox Business
09:16AM  Allergan and Actavis close to deal; Halliburton and Baker Hughes make it official; DreamWorks tumbles as Hasbro talks flop Hot Stock Minute
09:15AM  Halliburton, Baker Hughes Deal Resurrected at Bloomberg
09:15AM  Actavis to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenue PR Newswire
09:12AM  Stock Futures Set For Weak Open; Halliburton, Baker Hughes Merge at Investor's Business Daily
Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. It operates in three segments: Actavis Pharma, Actavis Specialty Brands, and Anda Distribution. The Actavis Pharma segment provides generic, branded generic, and over-the-counter (OTC) pharmaceutical products. This segment sells generic prescription products primarily under the Watson Laboratories, Watson Pharma, and Actavis Pharma labels; and OTC generic products under private label. The Actavis Specialty Brands segment offers patent-protected products and trademarked off-patent products, which are marketed as branded pharmaceutical products to physicians, specifically urologists, obstetricians, dermatologists, gastroenterologists, and gynecologists. The Anda Distribution segment primarily distributes generic and selected brand pharmaceutical products, vaccines, injectables, and OTC medicines to independent pharmacies, and to alternate care providers comprising hospitals, nursing homes, and mail order pharmacies, as well as to pharmacy chains, physicians' offices, and buying groups. The company also develops and out-licenses generic pharmaceutical products primarily in Europe through its third-party business; and provides products in women's health, urology, gastroenterology, and dermatology therapeutic categories. The company has a collaboration agreement with Amgen, Inc. for the development and commercialization of various oncology antibody biosimilar medicines; and a collaboration agreement with Hanmi Pharm. Co. Ltd. to develop Hyalrheuma, a hyaluronic acid injection for arthritis pain treatment. Actavis plc was founded in 1983 and is headquartered in Parsippany, New Jersey.